Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
Investing.com -- Today, pharmaceutical giant Eli Lilly and Company (NYSE: NYSE:LLY) unveiled the release of 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, now available for $499 under the Zepbound Self Pay Journey Program. In addition, Lilly has lowered the prices of the 2.5 mg and 5 mg vials. These offerings are accessible only through LillyDirect Self Pay Pharmacy Solutions, a service designed to provide transparent pricing by removing third-party supply chain entities and enabling patients to directly access savings outside of insurance.
Joe Nadglowski, president and CEO of the Obesity Action (WA:ACT) Coalition (OAC), appreciated Lilly’s efforts to make obesity treatment more affordable. He emphasized, however, the need for continued progress in creating a health care system offering comprehensive care, coverage, and payment for individuals with obesity, free of weight bias.
The new offerings provide self-pay patients with obesity a wider range of Zepbound vial options, such as 2.5 mg, 5 mg, 7.5 mg, and 10 mg doses. Lilly’s measures to make Zepbound vials more affordable include:
1. Reducing the price of the 2.5 mg dose to $349 per month.
2. Lowering the price of the 5 mg dose to $499 per month.
3. Introducing the Zepbound Self Pay Journey Program, which decreases the price of the 7.5 mg (originally $599) and 10 mg (originally $699) doses to $499 per month for the first fill and refills occurring within 45 days of the previous delivery.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.